Yahoo India Web Search

Sign In

Search results

  1. www.researchgate.net › Valery-Alakhov-39829292Valery Alakhov's research works | Supratek Pharma Inc ...

    Valery Alakhov's 56 research works with 7,311 citations and 4,835 reads, including: Rapamycin composition

  2. www.marketscreener.com › insider › VALERY-ALAKHOV-A0RJPKValery Alakhov: Positions, Relations and Network - MarketScreener

    Valery Alakhov is the founder of Supratek Pharma, Inc. He held the title of CSO and Vice President-Research & Development at the company since its founding in 1982.

  3. ca.linkedin.com › in › valery-alakhov-82a3a265Valery Alakhov - V-P R@D and CSO - Supratek Pharma Inc ...

    View Valery Alakhov’s profile on LinkedIn, the world’s largest professional community. Valery has 1 job listed on their profile. See the complete profile on LinkedIn and discover Valery’s...

    • 145
    • March 1, 1982
    • Supratek Pharma Inc.

  4. patents.justia.com › inventor › valery-alakhovValery Alakhov Inventions, Patents and Patent Applications ...

    Dec 23, 2013 · Valery Alakhov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  5. www.tandfonline.com › doi › absBlock copolymeric biotransport carriers as versatile vehicles ...

    Feb 23, 2005 · This review describes block copolymer-based systems that are used in drug formulation development. The use of amphiphilic block copolymers to modify pharmacological performance of various classes of drugs attracts more and more attention.

    • Valery Alakhov, Evgueni Klinski, Pierre Lemieux, Grzegorz Pietrzynski, Alexander Victorovich Kabanov
    • 2001

  6. pubmed.ncbi.nlm.nih.gov › 15992043Block copolymeric biotransport carriers as versatile vehicles ...

    This review describes block co-polymer-based systems that are used in drug delivery. The main focus is on amphiphilic block co-polymers, the application of which modifies the pharmacological performance of various classes of drugs and is attracting more and more attention.

  7. www.bioprocessonline.com › doc › suprateks-bioSupratek's BioTransport technology improves immune response ...

    Aug 28, 2000 · Valery Alakhov, vice president of research and development and chief scientific officer, presented results showing that SP1017 formulated with naked DNA coding for cancer specific genes produced a strong anti-cancer effect.